Amundi Protagonist Therapeutics, Inc Put Options Transaction History
Amundi
- $264 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding PTGX
# of Institutions
246Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$241 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$237 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$223 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$173 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$131 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.02B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...